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ABSTRACT:
Inactivating germline mutations in the tumor suppressor gene NF2 cause the 
hereditary syndrome neurofibromatosis 2, which is characterized by the development 
of neoplasms of the nervous system, most notably bilateral vestibular schwannoma.  
Somatic NF2 mutations have also been reported in a variety of cancers, but 
interestingly these mutations do not cause the same tumors that are common in 
hereditary neurofibromatosis 2, even though the same gene is involved and there is 
overlap in the site of mutations. This review highlights cancers in which somatic NF2 
mutations have been found, the cell signaling pathways involving NF2/merlin, current 
clinical trials treating neurofibromatosis 2 patients, and preclinical findings that 
promise to lead to new targeted therapies for both cancers harboring NF2 mutations 
and neurofibromatosis 2 patients.
INTRODUCTION
Neurofibromatosis type 2 (NF2) is a tumor 
suppressor gene on chromosome 22q12 that encodes 
a protein product named “merlin” (or schwannomin) 
affecting multiple cell signaling pathways (Figure 1)[1, 
2]. Constitutional mutations in the NF2 gene cause an 
autosomal-dominant disorder (neurofibromatosis type 
2) affecting about 1 in 33,000 people, and characterized 
by the development of tumors primarily affecting the 
nervous system[3]. Approximately half of the cases are 
due to de novo mutations not inherited from a family 
member [4]. NF2 mutations in neurofibromatosis 2 can 
either be germline (70%) or somatic mosaic (30%), the 
latter referring to mutations present in only a subset of 
cells[5, 6]. 
Neurofibromatosis 2 follows the Knudson 2-hit 
hypothesis, with constitutional (germline) mutations 
occurring initially (first hit) and additional somatic 
mutations (second hit) being required for loss of 
heterozygosity and tumor suppressor inactivation 
followed by tumor formation[7-9]. The majority of 
tumors associated with neurofibromatosis type 2 are 
schwannomas, meningiomas, and ependymomas[7]. 
Other than these specific tumor types, there is no published 
evidence to support an increased incidence of cancer in 
individuals with neurofibromatosis 2[7]. In general, in 
neurofibromatosis 2, constitutional nonsense or frameshift 
NF2 mutations are associated with more severe disease, 
while missense mutations, large deletions, or somatic 
mosaicism results in milder disease (fewer tumors and 
older age of onset) 
NF2 somatic mutations have also been found 
in multiple cancer types, including but not limited 
to mesothelioma, anaplastic thyroid cancer, breast 
cancers, endometrial and liver cancers, in patients not 
having constitutional NF2 mutations (Table 1)[10]. 
Missense mutations are more frequent in cancer than in 
neurofibromatosis 2; they occur in only a small subset of 
patients with latter condition. This may in part explain 
the lack of predisposition to developing cancer in patients 
with neurofibromatosis 2, though the explanation is not 
complete, since there remains considerable overlap 
between neurofibromatosis 2 and cancer-related NF2 
aberrations (Figure 2)[11, 12].
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Clinical Manifestations of Neurofibromatosis 2
The most common tumor associated with 
neurofibromatosis 2 is bilateral vestibular schwannoma 
(acoustic neuromas)[12, 13]. Initial symptoms of 
neurofibromatosis 2 include hearing loss, facial nerve 
impairment, visual disruptions, and skin tumors; with the 
majority of patients presenting before the age of 20[12]. 
Many patients with multiple tumor sites live only into 
their early thirties, and overall survival rate for patients 
20 years after diagnosis is approximately 40%[12, 13]. 
Treatment plans for patients with NF2 revolve around 
monitoring, surgery, and radiation therapy[12]. Due to 
recent advancements in our understanding of the signaling 
pathways affected by merlin, several targeted therapies are 
now being tested[14]. However, there remains a paucity of 
clinical trials, and a pressing need to accelerate the pace of 
testing in the clinical setting.
Merlin
The NF2 gene contains 17 exons and its product—
merlin—is a tumor suppressor that controls protean 
cell signaling pathways implicated in cell growth, 
proliferation, and morphology[15, 16]. Merlin acts as a 
membrane-cytoskeleton scaffolding (Ezrin–Radixin–
Moesin (ERM)) protein that localizes underneath the 
plasma membrane at cell–cell junctions and other actin-
rich sites[17, 18]. It links the cytoskeleton to the cell 
membrane.   Two isoforms of merlin have been described 
that differ by the presence (type 2 merlin) or absence 
(type 1 merlin; includes exons 1-15 and 17) of exon 16 
sequences inserted into the extreme carboxyl terminus of 
the protein. 
Myosin phosphatase MYPT1–PP1δ directly 
activates merlin by dephosphorylating it. Inactivation 
(phosphorylation) of merlin contributes to malignant 
conversion in multiple cell types, as does loss of merlin 
expression because of mutation [19]. Importantly, 
phosphorylation not only causes the conformation of 
merlin to change to the open/inactive state, but also 
targets merlin for polyubiquitination and degradation by 
the proteasome [19-21]. The decreased ability of mutant 
merlin to effectively act as a tumor suppressor is at least 
in part a direct result of the decreased half-life of mutant 
compared to wild-type merlin[22, 23].
Functions of NF2/merlin
Several different signaling pathways crucial to 
cell proliferation are inhibited by merlin: PIKE-L/PI3K, 
mTORC1, Src/Fak, Mst1/2, Ras/Rac/PAK, ERK1/2, AKT 
and CRL4-DCAF (Figure 1)[1, 24, 25]. Merlin also acts 
as an unconventional cell cycle regulator, and it links 
Figure 1: Merlin affects key signaling pathways in the cytoplasm and nucleus. Merlin inhibits PI3K signaling cascade at 
PIKE-L[19, 30] and mTORC1[32, 33]. The RAS and Src pathways are inhibited by merlin via the Src/FAK complex[34, 36]. Transcription 
is inhibited by merlin via Hippo kinase cascade[81, 82] and CRL4-DCAF[83]. Merlin can also down-regulates cell surface growth factor 
receptors. Dotted line indicates nuclear membrane. Targeted therapies are indicated in red.  
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receptors at the plasma membrane to their cytoplasmic 
kinases to facilitate contact inhibition [26, 27].
PI3K/PIKE-L:  
The phosphatidylinositol 3-kinase (PI3K) pathway 
is activated in multiple human cancers, and contributes 
to increased cellular proliferation and metabolism, and 
decreased apoptosis when activated[28, 29]. Merlin 
suppresses the PI3K pathway by binding with the PI3K-
enhancer-isoform-L (PIKE-L), hence preventing PIKE-L 
from binding PI3K[30, 31].
mTORC1: 
 Inhibition of mammalian-target-of-rapamycin-
complex-1 (mTORC1) due to merlin activation leads 
to the inhibition of mRNA translation, which causes an 
increase in apoptosis limiting cell survival and blocking 
tumor initiation[32]. mTORC1 inhibition is accomplished 
through multiple pathways including AKT/ERK inhibition 
and integrin specific adhesion via p21-activated kinase 
(PAK)[32, 33]. mTORC1 has also been identified as an 
important pathway in meningioma and schwannoma cell 
growth[33].
ErbB2/Src/FAK/Paxillin: 
 Merlin binds the receptor ErbB2 and also to Src, 
inhibiting Src from binding to and being phosphorylated 
by ErbB2 in a competitive manner [34].  As a result, Src 
cannot activate focal adhesion kinase (FAK) and paxillin, 
which inhibits cellular proliferation and growth[34]. 
Interestingly, binding of merlin to ErbB2 is initiated by 
paxillin binding to merlin on exon 2 at residues 50-70, 
causing merlin to move to the plasma membrane where it 
binds ErbB2[35].  Merlin also inhibits FAK from binding 
to Src and PI3K [36].
ERK1/2, AKT, and PDGFR:  
 Schwannoma cell lines lacking the tumor 
suppressor activity of merlin have high basal levels of 
phosphorylated extracellular signal-regulated kinase 
(ERK1/2) and AKT, which are activated by the Src/FAK/
Ras and PI3K/Raf signaling cascades and platelet-derived 
Figure 2: Constitutional and somatic NF2 mutations in neurofibromatosis 2 and somatic NF2 mutations in cancer.  NF2 
mutations have been found in neurofibromatosis 2 and also in numerous cancers[15]. Shown are the non-truncating constitutional and somatic 
mutations found in neurofibromatosis 2 [blue boxes] and non-truncating (missense) and truncating (nonsense or frameshift) mutations 
found in human cancer [black boxes][84]. Gray boxes indicate constitutional mutations while white boxes indicate somatic mutations. 
Because there are numerous truncating lesions found in neurofibromatosis 2[69] and in non-hereditary meningiomas, ependymomas, and 
schwannomas,[69, 85] these could not be depicted in figure 2. Truncating lesions that are found in both neurofibromatosis 2 and cancer 
are shown in red. Missense mutations that are found in both neurofibromatosis 2 and cancer are also shown in red followed by [mis]. 
Termination sites of translation for frameshift mutations is indicated with an (*) and for nonsense mutations with an (X).
Oncotarget70www.impactjournals.com/oncotarget
growth factor receptor beta (PDGFRβ) (Figure 1)[37]. 
Merlin inhibits the activity of ERK and MAPK via the 
upstream effector Raf-1[38, 39]. In normal cells, merlin 
promotes PDGFRβ degradation as well, thereby inhibiting 
cellular proliferation [37, 40]. In a positive feedback loop, 
activated AKT also binds and phosphorylates merlin on 
residues Thr230 and Ser315, which causes merlin to be 
ubiquitinated and targeted for degradation[19, 20, 41]. 
Rac/PAK: 
 Due to merlin’s sequence homology with ERM 
proteins, merlin binds the same proteins, but unlike 
ERM proteins merlin acts in an inhibitory manner by 
suppressing cell growth and proliferation [42, 43]. 
Merlin may suppress the oncogenic signaling of the 
small GTPases Ras and Rac by interfering with guanine 
Table 1: Cancers associated with NF2 somatic mutations
Cancer Type
% Containing NF2 
Somatic Mutations 
Source
Acute myelogenous leukemia (AML) 2%                 (1/45)
Yoo et al, Pathology 2012 [9]
COSMIC 
Aerodigestive tract (Squamous cell 
carcinoma)
4%                 (1/23) COSMIC 
Bladder 3%                 (1/14) Iyer G et al., Science 2012 [66]
Bone (sarcoma) 6%                 (2/34) COSMIC 
Breast Cancer 1-2%   (3/387) (1/42) 
COSMIC 
ICGC Data Portal  (http://dcc.icgc.org)
Bianchi et al, Nature Genetics 1994[13] 
Sjöblom T et al, Science 2006 [63] 
Ikediobi et al, Mol Cancer Ther 2006[64]
Ependymoma* 4%             (18/433) COSMIC 
Colorectal Carcinoma 5%                 (2/44) Arakawa H et al, HMG 1994 [87]
Endometrium (mixed adenosquamous 
carcinoma)
10%               (1/10) COSMIC 
Glioma 27%          (37/135) Lau YK et al, Cancer Res 2008[25]
Hepatocellular Carcinoma (HCC) 2%                 (1/45)
Yoo et al, Pathology 2012 [9]
COSMIC 
Intestine (large) 2%               (8/335) COSMIC 
Liver Cancer 23%             (17/75) ICGC Data Portal  (http://dcc.icgc.org)
Lung (Adenocarcinoma) 1%               (1/163) ICGC Data Portal  (http://dcc.icgc.org) 
Lung (Mixed) 1%               (3/586) COSMIC 
Lung (Squamous Cell Carcinoma) 2%                 (1/45)
Yoo et al, Pathology 2012 [9]
COSMIC 
Melanoma 5%               (6/126)
COSMIC 
Bianchi et al, Nature Genetics 1994 [13]
Meningioma * 31%       (363/1164) COSMIC 
Mesothelioma 30-50%         (8/27)
COSMIC 
Carbone and Yang, CCR 2012 [88] 
Sekido Y, et al, Cancer Res 1995 [89] 
Bianchi AB, et al. Proc Natl Acad Sci  1995 [90]
Ovary (serous carcinoma) 1%               (2/149) COSMIC 
Pituitary 100%               (1/1)           
 COSMIC 
Szijan et al, Neuromolecular Med 2003 [91]
Renal cell carcinoma 1-2% (5/412) (7/428)     
Staller P, Future Oncology 2010 [92]
COSMIC 
Schwannoma * 42%         (271/647) COSMIC 
Stomach 3%                 (2/66) COSMIC 
Thyroid (anaplastic carcinoma) 18%               (2/11) COSMIC 
Urinary tract 11%               (2/18) COSMIC 
*Sporacic tumors, patients do not have neurofibromatosis 2
  COSMIC (http://www.sanger.ac.uk/cosmic) 
Oncotarget71www.impactjournals.com/oncotarget
nucleotide-exchange factor (GEF) activity, which is 
required for Ras and Rac activation[43, 44]. Merlin 
inhibits signaling of the Ras pathway downstream by 
inhibiting Rac activation, which results in the inhibition of 
phosphorylation/activation of the serine/threonine kinase 
PAK [43]. When PAK is not phosphorylated it is unable to 
phosphorylate RAF and MEK, which are both necessary 
to activate the Ras signaling pathway[43, 45].
NF2 mutations in cancer
Data collected from COSMIC and ICGC databases 
and published studies show that diverse cancers harbor 
somatic NF2 mutations (Table 1).  
Thoracic tumors (mesothelioma and lung cancer):  
The most common cancer linked to NF2 aberrations 
is mesothelioma, with approximately 30-50% of tumors 
having mutations in the NF2 coding regio[22, 46-48]. 
The NF2 mutations found in neurofibromatosis 2 differ 
from the mutations found in mesotheliomas in that 
mutations in hereditary NF2 are not usually missense 
mutations. Only ~5% of neurofibromatosis 2 patients 
have constitutional missense mutations and these types of 
mutations are typically associated with a milder version 
of NF2 [49, 50].  This dichotomy may partially explain 
why patients with neurofibromatosis 2 do not develop 
mesothelioma[51].  A variety of lung cancers have also 
been found to harbor NF2 mutations, but at a much lower 
rate (1-2%)[11]. 
Sporadic schwannomas, meningiomas, and 
ependymomas:  
Sporadic schwannomas, meningiomas, and 
ependymomas fund in patients who do not suffer from 
constitutional neurofibromatosis 2 have somatic NF2 
mutations at rates of 42%, 27%, and 4%, respectively[46]. 
These are also the most prevalent tumor types found 
in individuals with constitutional NF2 mutations[7]. 
Mutations found in these sporadic tumors tend to 
include more frameshift mutations, while those found in 
neurofibromatosis 2 are often nonsense mutations[52, 53]. 
Thyroid cancer: 
 NF2 mutations have also been discerned in 
18% (two of 11) anaplastic thyroid cancers. These are 
uncommon (accounting for only 2% of all thyroid cancers) 
but very aggressive cancers, with a median survival 
of only a few months[54].  Of interest, other pathways 
(PIK3/AKT/MTOR, RAS/RAK and ERK) activated via 
mutation in this cancer type are negatively regulated by 
active merlin [54-59]. 
Breast cancer: 
 One to two percent of breast cancers have NF2 
mutations [15, 60-62]. A decrease in merlin expression 
correlates with increase in tumor grade [47].  When merlin 
expression is reestablished in breast xenograft models, 
tumorigenesis is reduced [47]. Since NF2 mutations 
activate mTor, we treated a patient with NF2-mutant 
metaplastic breast cancer (a highly refractory form of 
breast cancer) with a temsirolimus-based regimen, which 
resulted in a complete remission [63].  
Glioblastoma multiforme: 
  Decreased expression of merlin RNA and protein 
levels have been observed in several human glioblastoma 
multiforme tumors; 27% of grade 4 gliomas have loss of 
merlin expression [46]. Merlin decreases proliferation and 
invasiveness while increasing apoptosis-induced cell death 
when its tumor suppressor capabilities are reestablished in 
the corresponding glioma cell lines [46]. 
Endometrial cancer: 
Ten percent of endometrial carcinomas harbor 
NF2 mutations. This observation is of interest since NF2 
mutations can activate mTor, the downstream effector 
of PIK3CA, and a high percentage of this cancer type 
(>80%) have PI3K pathway aberrations [30, 64].   
Hepatocellular tumors: 
Twenty-three percent of liver cancers have 
mutations in NF2.  Mice with heterozygous NF2 mutations 
develop hepatocellular carcinoma and cholangiocarcinoma 
[65, 66].
Comparing NF2 aberrations in hereditary 
neurofibromatosis and in cancer
Overlap in truncating and non-truncating mutations 
found in cancers and hereditary neurofibromatosis 2 are 
shown in Figure 2 (red lettering). There have not been 
any mutations found in exons 16 and 17, which are 
the two exons affected by alternative splicing, and no 
known proteins have been found to bind to exon 16[33, 
67]. Tumor suppressor activity can be attenuated by 
truncating mutations in any of the other exons 1-15[68]. 
In neurofibromatosis 2, truncating mutations (frameshift 
and nonsense) are associated with an increase in disease 
severity when compared with missense mutations[7]. 
Nonsense mutations are more frequent in hereditary 
neurofibromatosis 2 than in sporadic schwannomas, 
ependymomas, and meningiomas where frameshift 
mutations are more common [53, 69]. Missense mutations 
are more frequent in cancer, but occur in only about 5% of 
hereditary neurofibromatosis 2. 
There are several binding sites in the merlin protein 
that are crucial for merlin’s function, being critical to 
interactions with other proteins or for correct merlin 
folding and activation. Merlin must associate with itself 
in order to change conformation and become active. 
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This is achieved first by the folding of the N-terminal 
domain, which involves the interaction of amino acids 
8-121 with amino acids 200-320[67, 70]. After the 
conformational change of the N-terminus is complete, 
merlin can transition to the active, closed conformation 
by the association of the N-terminal amino acids 302-308 
with the C-terminal amino acids 580-595[67, 70]. When 
examining Figure 2, it is remarkable that no mutations are 
found in the region where the C-terminus and N-terminus 
interact, but multiple mutations are found in the regions 
where the N-terminus interacts with itself. 
The phosphatase (MYPT1-PP1δ) responsible for 
the dephosphorylation and activation of merlin (at residue 
S518) interacts with merlin via its MYPT1 subunit at 
residues 312-341 of merlin (exons 10 and 11)[67]. As 
shown in figure 2, this region has multiple missense 
mutations in both cancer and NF2.
P21-activating kinases (PAK) are regulated 
by merlin and also regulate the activity of merlin by 
phosphorylating S518 and causing merlin to change to 
the open, inactive state[67]. PAKs interact with merlin 
at the N-terminus between amino acids 1-313, and 
there are many missense mutations in both cancer and 
neurofibromatosis 2 found within this region (Figure 2)
[67]. 
PIKE-L binds to merlin in the region containing 
amino acids 1-332, whereas mutant merlin harboring 
the L64P missense mutation does not bind PIKE-L[30, 
67]. Importantly, merlin cannot suppress tumorigenesis, 
including cellular proliferation, via inhibition of the PI3K 
pathway without binding to PIKE-L[30, 67]. Merlin’s 
interaction with PIKE-L could also regulate downstream 
effectors of PI3K such as AKT and mTOR[67]. The L64P 
mutation has not been found in any cancers but is reported 
in neurofibromatosis 2. 
Clinical Trials
Novel targeted therapies are now being used in a 
small number of cases to treat hereditary neurofibromatosis 
2 and cancers harboring NF2 mutations (Table 2). The vast 
majority of these trials are ongoing and results are not yet 
published.  A search of clinicaltrials.gov was undertaken in 
order to find clinical trials treating NF2 patients.
Receptor tyrosine kinase (RTK) Inhibitors:   
Lapatinib, which targets EGFR and ErbB-2, 
is being examined in both a phase 0 study treating 
vestibular schwannomas (NCT00863122) and a phase 
II (NCT00973739) trial for its effectiveness in all NF2 
related tumor types. Clinical analysis has shown that 
vestibular schwannomas overexpress ErbB2/3 and that 
EGFR and its ligand are up-regulated in the majority of 
NF2-related vestibular schwannomas[71, 72].  
Sporadic and neurofibromatosis 2-related vestibular 
schwannomas overexpress c-kit and PDGFR, which are 
targets of the receptor tyrosine kinase (RTK) inhibitor 
imatinib. In vitro studies using the vestibular schwannoma 
cell line HEI-193 show a decrease in proliferation and 
an increase in apoptosis in response to treatment with 
imatinib. Currently sunitinib and nilotinib, are being 
tested in patients with neurofibromatosis 2[13].   Sunitinib 
is an RTK inhibitor that targets multiple receptors such as 
PDGFR, VEGFR, and c-KIT. Two phase II clinical trials 
are currently evaluating the effectiveness of sunitinib 
in unresectable meningiomas (NCT00561665) and 
(NCT00589784). Nilotinib is a RTK inhibitor that targets 
Bcr-Abl, PDGFR, and c-Kit, and is also being used in 
a phase II clinical trial (NCT01201538) focusing on 
progressing vestibular schwannomas.
Table 2: Ongoing Clinical Trials for Neurofibromatosis 2 Patients
Drug Name Mechanism
Phase of 
Study
Trial Reference Number
Lapatinib Dual tyrosine kinase inhibitor (Her2/EGFR) Phase 0 NCT00863122
PD-0332991 CDK inhibitor Phase 1 NCT01602887
Bevacizumab Anti-VEGF monoclonal antibody Phase 2 NCT01207687, NCT01125046
Everolimus 
(RAD-001)
mTOR inhibitor Phase 2
NCT01490476, NCT01345136, 
NCT01419639
Lapatinib ErbB2/EGFR inhibitor Phase 2 NCT00973739
Nilotinib
Receptor tyrosine kinase  inhibitor (Bcr-Abl, 
PDGFR, c-KIT)
Phase 2 NCT01201538
PTC299 Decrease production of VEGF Phase 2 NCT00911248
Sunitinib 
Receptor tyrosine kinase  inhibitor (PDGFR, 
VEGFR, c-KIT)
Phase 2 NCT00561665, NCT00589784
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Vascular Endothelial Growth Factor (VEGF) 
Inhibitors:   
Bevacizumab is an anti-VEGF monoclonal antibody 
that inhibits angiogenesis, slowing tumor growth and 
formation.  Schwannomas produce high levels of VEGF. 
In a study of ten NF2 patients treated with bevacizumab, 
nine had tumor shrinkage, and seven experienced hearing 
improvement. Two phase II clinical trials (NCT01207687, 
NCT01125046) are assessing the effectiveness of 
bevacizumab in treating neurofibromatosis 2 patients with 
symptomatic vestibular schwannomas and recurrent or 
progressive meningiomas. Another drug PTC299 targets 
VEGF by inhibiting its synthesis upstream and interfering 
with post-transcriptional processing [73]. PTC299 has 
been studied in neurofibromatosis 2 patients via a phase 
II clinical trial [73]. 
mTOR Inhibitors:  
 Everolimus (RAD-001) is an mTOR inhibitor. 
Merlin is a negative regulator of mTOR. Therefore, in 
patients with deactivating NF2 mutations, one could 
hypothesize that an mTOR inhibitor would restore 
merlin’s inhibition of mTOR and arrest tumor formation 
[32]. There are three phase II clinical trials using 
everolimus to treat NF2-related tumors: NCT01490476, 
NCT01345136 and NCT01419639. A fourth phase II 
clinical trial (NCT01024946) is available for treatment of 
malignant pleural mesotheliomas using NF2/merlin loss as 
a biomarker to predict everolimus sensitivity. The mTOR 
inhibitor temsirolimus was tried in combination with the 
anti-VEGF antibody bezacizumab in a clinical case series 
focusing on patients with neurofibromatosis 2; of the two 
patients on this regimen, one achieved a 33% reduction in 
tumor size[74]. Of interest, one patient with metaplastic 
breast cancer who harbored an NF2 mutation achieved a 
complete remission on a temsirolimus-containing regimen 
[63].  
RAS and CDK inhibitors:  
Merlin blocks RAS activation.  When merlin 
activity is lost, RAS can then move into the active state 
and promote cell growth and proliferation [13]. S-trans, 
trans-farnesyl-thiosalicylic-acid (FTS) is a RAS inhibitor 
that was administered to two patients with hereditary 
neurofibromatosis 2, one of whom achieved stable disease 
for over 4.5 years[74, 75]. 
Preclinical Studies
Treatment of human schwannoma cells in vitro with 
curcumin (diferuloylmethane), caused dephosphorylation 
of AKT and ERK1/2 and activation of the merlin 
phosphatase MYPT1-pp1δ, which is responsible for the 
dephosphorylation of S518 [76]. Interestingly, hsp70 was 
up-regulated following curcumin treatment, which could 
serve as a resistance mechanism. Hence, a heat shock 
protein inhibitor (KNK437) was used in combination with 
curcumin to block this potential resistance mechanism 
[76]. Merlin loss also causes constitutive activation of 
receptor tyrosine kinases (EGFR, ErbB2, and ErbB3), 
which can be targeted by EGFR and ErbB2 inhibitors 
such as erlotinib or lapatinib[13]. Finally, sorafinib, a 
PDGFR and c-RAF inhibitor has been shown to decrease 
proliferation in human schwannoma cell line [37].
CONCLUSIONS
NF2 is a complex gene with somatic mutations 
being associated with various cancers (e.g. 30 to 50 
percent of mesotheliomas harbor NF2 mutations (Table 
1)).  Germline mutations cause the autosomal dominant 
disorder neurofibromatosis 2. Although the somatic 
mutations sometimes overlap with those in hereditary NF2 
(Figure 2), there are no published papers documenting an 
increased risk of cancer in neurofibromatosis patients; 
individuals with hereditary NF2  do develop schwannomas, 
ependymomas, and meningiomas. Though there is overlap 
in the types of NF2 mutations/aberrations between NF2-
related conditions (Figure 2), nonsense mutations are more 
frequent in neurofibromatosis 2, frameshift mutations in 
sporadic schwannomas, meningiomas, and ependymomas, 
and missense mutations in cancer[69]. 
 Merlin inhibits PIK3CA and mTOR function 
along with several other pathways including Src/Fak, 
Mst1/2 (hippo), Ras/Rac/PAK, ERK1/2, AKT and CRL4-
DCAF (Figure 1). A small series of mostly anecdotal 
reports describe activity for anti-angiogenesis agents 
(bevacizumab), a RAS inhibitor, and the mTor inhibitor 
temsirolimus in patients with hereditary neurofibromatosis 
2[74, 77]. In patients with malignancy, an increasing 
number of studies have established that matching 
targeted therapy to even a single aberration in patients 
whose tumors harbor multiple genomic abnormalities 
can at times result in remarkable responses[78-80]. 
Since neurofibromatosis 2, unlike cancer, is a single 
gene disorder, it seems conceivable that proper targeting 
would result in tumor regressions. In order to explore this 
possibility, a variety of relevant agents should be explored 
in the clinical setting. This is especially important 
because of the morbidity and mortality associated with 
neurofibromatosis 2, and because many agents that 
impact NF2-related pathways are already available. 
Rare conditions are an accrual challenge for larger trials. 
Therefore, pilot trials whose aim is tumor response may be 
a mechanism to initially establish activity of an agent, and 
more of these trials are urgently warranted.
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